Who is sponsoring NCT07343206?

NCT07343206 is sponsored by Siriraj Hospital.

What drugs are being tested in NCT07343206?

Interventions in NCT07343206: Early norepinephrine administration and rapid dose adjustment, Control.

What condition does NCT07343206 study?

NCT07343206 studies Sepsis, Septic Shock.

Is NCT07343206 still recruiting?

NCT07343206 is currently recruiting now. Last updated 21 April 2026.

Last reviewed 2026-04-21 · How we verify

NCT07343206: CENSER2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Early Norepinephrine Administration and Rapid Dose Adjustment in Adult Septic Shock Patients: A Multicenter Randomized Controlled Trial

Recruiting now NA Last updated 21 April 2026

What this trial tests

NA trial testing Early norepinephrine administration and rapid dose adjustment in Sepsis in 600 participants. Currently enrolling.

Timeline

1 January 2026

Primary endpoint
1 January 2028

1 March 2028

Quick facts

Lead sponsor	Siriraj Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	600
Start date	1 January 2026
Primary completion	1 January 2028
Estimated completion	1 March 2028
Sites	6 locations across Thailand

Drugs / interventions tested

Early norepinephrine administration and rapid dose adjustment — full drug profile →
Control

Conditions studied

Sepsis — all drugs for Sepsis →
Septic Shock — all drugs for Septic Shock →

Sponsor

Siriraj Hospital

Who can join

18 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

28-day survival
Time frame: From enrollment to 28 days after enrollment
Survival at 28-day after enrollment. Telephone follow-up for patients who are discharged before 28 days.

Sponsor's own description

The goal of this clinical trial is to determine whether early initiation of norepinephrine with rapid dose adjustment improves clinical outcomes in adult patients with septic shock. The study aims to evaluate the effect of early norepinephrine administration on mortality, hemodynamic stabilization, and resuscitation efficiency in adults aged 18 years and older diagnosed with septic shock. The main questions it aims to answer are: * Does early norepinephrine administration with rapid dose titration reduce 28-day mortality compared with standard treatment? * Does early norepinephrine administration with rapid dose tiration lead to faster shock control and reduced fluid requirements without increasing treatment-related adverse events? Researchers will compare early norepinephrine administration with rapid dose adjustment to placebo with standard sequential resuscitation and rescue norepinephrine as needed to see if early vasopressor initiation improves survival, shock resolution, and safety outcomes. Participants will: * Receive either norepinephrine or placebo infusion initiated within one hour of septic shock diagnosis, with dose adjustment every 15 minutes according to a standardized protocol * Undergo close hemodynamic and safety monitoring, including frequent vital sign assessment and limb perfusion evaluation * Receive standard sepsis care, including fluid resuscitation, antibiotics, and organ support as clinically indicated * Be followed for clinical outcomes and adverse events for up to 28 days after enrollment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Siriraj Hospital trials

Trials by the same sponsor.

NCT07262034 — The Impact of Preoperative Nutrition Intervention on Muscle Mass Preserve in Older Adults Undergoing Elective Surgery · not yet recruiting
NCT07402486 — A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer · Phase 2 · not yet recruiting
NCT07298577 — Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ult · NA · not yet recruiting
NCT07239908 — Resuscitation Enhancement to Avoid Rearrest Through Evidence-based Strategies in Prehospital Post-resuscitation Care · Phase 2, PHASE3 · not yet recruiting
NCT07110961 — The Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Diagnosis of Restless Legs Syndro · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07343206 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Siriraj Hospital
Last refreshed: 21 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07343206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing